IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6

Stefan Rose-John, Stefan Rose-John

Abstract

Interleukin-6 (IL-6) is a cytokine with many activities. It has functions in the regulation of the immune system and the nervous system. Furthermore, IL-6 is involved in liver regeneration and in the metabolic control of the body. On target cells, IL-6 binds to an 80 kDa IL-6 receptor (IL-6R). The complex of IL-6 and IL-6R associates with a second protein, gp130, which thereupon dimerizes and initiates intracellular signaling. Whereas gp130 is expressed on all cells, IL-6R is only present on few cells in the body including hepatocytes and some leukocytes. Cells, which do not express IL-6R cannot respond to the cytokine, since gp130 alone has no measurable affinity for IL-6. Interestingly, a soluble form of IL-6R (sIL-6R) comprising the extracellular portion of the receptor can bind IL-6 with a similar affinity as the membrane bound IL-6R. The complex of IL-6 and sIL-6R can bind to gp130 on cells, which do not express the IL-6R, and which are unresponsive to IL-6. This process has been called trans-signaling. Here I will review published evidence that IL-6 trans-signaling is pro-inflammatory whereas classic IL-6 signaling via the membrane bound IL-6R is needed for regenerative or anti-inflammatory activities of the cytokine. Furthermore, the detailed knowledge of IL-6 biology has important consequences for therapeutic strategies aimed at the blockade of the cytokine IL-6.

Keywords: IL-6; IL-6 receptor; inflammation; inflammation associated cancer.; shedding; soluble receptor.

Conflict of interest statement

Competing Interests: Dr. Rose-John is an inventor on patents describing the function of sgp130Fc. He is also a shareholder of the CONARIS Research Institute (Kiel, Germany), which is commercially developing sgp130Fc proteins as therapeutics for inflammatory diseases.

Figures

Fig 1
Fig 1
IL-6 classic- signaling and IL-6 trans-signaling. IL-6 Classic-signaling requires membrane bound IL-6R and is restricted to hepatocytes, some epithelial cells and some leukocytes. IL-6 trans-signaling requires sIL-6R and is possible on all cells of the body since all cells express the gp130 protein.
Fig 2
Fig 2
Receptor distribution IL-6R expressing cells. Most IL-6R expressing cells express far more gp130 than IL-6R. IL-6 stimulation of such cells leads to the activation of only few gp130 molecules. IL-6 in the presence of the sIL-6R, however, will lead to stimulation of all gp130 molecules leading to a higher signal amplitude.
Fig 3
Fig 3
Designer proteins for the study of IL-6 signaling. (A) Hyper-IL-6 is a fusion protein between the sIL-6R (blue) and IL-6 (brown). In a molecular model, the C-terminus of sIL-6R was 40 Å apart from the N-terminus of IL-6. Therefore, we inserted a flexible peptide linker between sIL-6R and IL-6 (black) to connect both molecules. (B) The sgp130Fc protein consists of the extracellular portion of gp130 linked to the Fc domain of a human IgG1 antibody. The sgp130Fc protein blocks IL-6 trans-signaling without affecting IL-6 classic signaling. (C) In the L-gp130 protein, the entire extracellular portion of gp130 is replaced by the leucine zipper of the Jun protein, leading to constitutive dimerization and activation of the gp130 protein. This protein can be used to study the effects of permanent gp130 activation in transfected cells or in tissue specific transgenic animals.
Fig 4
Fig 4
Pro- and anti-inflammatory activities of IL-6. Anti-inflammatory activities of IL-6 include STAT3 dependent regeneration of epithelial cells and the induction of the hepatic acute phase response. These activities are dependent on the membrane bound IL-6R. Pro-inflammatory activities of IL-6 include recruitment of inflammatory cells, inhibition of apoptosis of inflammatory cells and inhibition of regulatory T-cell differentiation.
Fig 5
Fig 5
Consequences of specific IL-6 trans-signaling blockade by sgp130Fc. The sgp130Fc protein only binds to IL-6 molecules, which are complexed with sIL-6R. Therefore, in the presence of an excess of IL-6, not all IL-6 molecules are neutralized and can induce regeneration of epithelial cells or trigger the hepatic acute phase response.

References

    1. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324:73–6.
    1. Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today. 1990;11:350–4.
    1. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B. et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988;241:825–8.
    1. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149–57.
    1. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.
    1. Scheller J, Grötzinger J, Rose-John S. Updating IL-6 classic- and trans-signaling. Signal Transduction. 2006;6:240–59.
    1. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004;20:23–32.
    1. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW. et al. Therapeutic targeting of IL-6 trans-signaling counteracts STAT3 control of the inflammatory infiltrate in experimental arthritis. J Immunol. 2009;182:613–22.
    1. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121:3375–83. doi:10.1172/JCI57158.
    1. Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol. 2005;23:1–21.
    1. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N. et al. Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem. 2001;268:160–7.
    1. Fischer M, Goldschmitt J, Peschel C, Kallen KJ, Brakenhoff JPJ, Wollmer A. et al. A designer cytokine with high activity on human hematopoietic progenitor cells. Nat Biotech. 1997;15:142–5.
    1. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989;170:1409–14.
    1. Müllberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G. et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23:473–80.
    1. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 1992;4:96–100.
    1. Dimitrov S, Lange T, Benedict C, Scheller J, Rose-John S, Jones S. et al. Sleep Enhances IL-6 Trans-Signaling in Humans. Faseb J. 2006;20:2174–2176.
    1. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch of inflammatory and regenerative responses? Trends Immunol. 2011;32:380–387.
    1. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300:281–90.
    1. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T. et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573–81.
    1. Müllberg J, Schooltink H, Stoyan T, Heinrich PC, Rose-John S. Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun. 1992;189:794–800.
    1. Müllberg J, Oberthur W, Lottspeich F, Mehl E, Dittrich E, Graeve L. et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol. 1994;152:4958–68.
    1. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189:599–604.
    1. Walev I, Vollmer P, Palmer M, Bhakdi S, Rose-John S. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci USA. 1996;93:7882–7.
    1. Matthews V, Schuster B, Schütze S, Kallen K-J, Rose-John S. Cholesterol depletion of the plasma membrane triggers shedding of the human interleukin-6 receptor by TACE and independently of PKC. J Biol Chem. 2003;278:38829–39.
    1. Vollmer P, Walev I, Rose-John S, Bhakdi S. Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun. 1996;64:3646–51.
    1. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA. et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the pro-inflammatory trans-signaling function of neutrophils. Blood. 2007;110:1748–55.
    1. DeLeo FR. Attractive shedding. Blood. 2007;110:1711–2.
    1. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.
    1. Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J. et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol. 2007;179:2041–5.
    1. Briso EM, Dienz O, Rincon M. Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells. J Immunol. 2008;180:7102–6.
    1. Jones GW, McLoughlin RM, Hammond VJ, Parker CR, Williams JD, Malhotra R. et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol. 2010;184:2130–9.
    1. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y. et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120–6.
    1. Zhang JG, Zhang Y, Owczarek CM, Ward LD, Moritz RL, Simpson RJ. et al. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor alpha-chain in normal human urine and plasma. J Biol Chem. 1998;273:10798–805.
    1. Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S. et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthr Rheumat. 2006;54:1662–72.
    1. Müllberg J, Dittrich E, Graeve L, Gerhartz C, Yasukawa K, Taga T. et al. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett. 1993;332:174–8.
    1. Diamant M, Hansen MB, Rieneck K, Svenson M, Yasukawa K, Bendtzen K. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. Leuk Res. 1996;20:291–301.
    1. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E. et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183:1399–406.
    1. van Dam M, Müllberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L. et al. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem. 1993;268:15285–90.
    1. Fattori E, Della Rocca C, Costa P, Giorgio M, Dente B, Pozzi L. et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood. 1994;83:2570–9.
    1. Peters M, Schirmacher P, Goldschmitt J, Odenthal M, Peschel C, Dienes HP. et al. Extramedullary expansion of hematopoietic progenitor cells in IL-6/sIL-6R double transgenic mice. J Exp Med. 1997;185:755–66.
    1. Schirmacher P, Peters M, Ciliberto G, Fattori E, Lotz J, Meyer zum Büschenfelde KH. et al. Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extracellular Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mice. Am J Pathol. 1998;153:639–48.
    1. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M. et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. Embo J. 1998;17:5588–97.
    1. Peters M, Müller A, Rose-John S. Interleukin-6 and soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis. Blood. 1998;92:3495–504.
    1. Dittrich E, Rose-John S, Gerhartz C, Mullberg J, Stoyan T, Yasukawa K. et al. Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J Biol Chem. 1994;269:19014–20.
    1. Peters M, Blinn G, Solem F, Fischer M, Meyer zum Büschenfelde K-H, Rose-John S. In Vivo and in vitro Activity of the gp130 Stimulating Designer Cytokine Hyper-IL-6. J Immunol. 1998;161:3575–81.
    1. Rose-John S, Schooltink H, Lenz D, Hipp E, Dufhues G, Schmitz H. et al. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur J Biochem. 1990;190:79–83.
    1. Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ. Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic cells. Proc Natl Acad Sci USA. 2001;98:1757–62.
    1. März P, Cheng J-C, Gadient RA, Patterson P, Stoyan T, Otten U. et al. Sympathetic Neurons can produce and respond to Interleukin-6. Proc Natl Acad Sci USA. 1998;95:3251–6.
    1. März P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. Role of Interleukin-6 and soluble IL-6 Receptor in Region Specific Induction of Astrocytic Differentiation and Neurotrophin Expression. Glia. 1999;26:191–200.
    1. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel Path of activation of primary human smooth muscle cells: upregulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999;163:4583–9.
    1. Viswanathan S, Benatar T, Rose-John S, Lauffenburger DA, Zandstra PW. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem cells (Dayton, Ohio) 2002;20:119–38.
    1. Humphrey RK, Beattie GM, Lopez AD, Bucay N, King CC, Firpo M. et al. Maintenance of pluripotency in human embryonic stem cells is Stat3 independent. Stem cells (Dayton, Ohio) 2004;22:522–30.
    1. Rose-John S, Scheller J, Elson G, Jones S. Interleukin-6 Biology is Coordinated by Membrane-Bound and Soluble Receptors: Role in Inflammation and Cancer. J Leuk Biol. 2006;80:227–36.
    1. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007;11:613–24.
    1. Waetzig GH, Rose-John S. Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets. 2012;16:225–36.
    1. Scheller J, Schuster B, Holscher C, Yoshimoto T, Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun. 2005;326:724–8.
    1. Giese B, Roderburg C, Sommerauer M, Wortmann SB, Metz S, Heinrich PC. et al. Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. Journal of cell science. 2005;118:5129–40.
    1. Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, Kallen KJ. et al. gp130 Dimerization in the Absence of Ligand: preformed Cytokine Receptor Complexes. Biochem Biophys Res Commun. 2006;346:649–57.
    1. Stuhlmann-Laeisz C, Lang S, Chalaris A, Paliga K, Sudarman E, Eichler J. et al. Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine independent growth and blockade of differentiation of embryonic stem cells. Mol Biol Cell. 2006;17:2986–95.
    1. Suthaus J, Tillmann A, Lorenzen I, Bulanova E, Rose-John S, Scheller J. Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell. 2010;21:2797–807.
    1. Schuster B, Meinert W, Rose-John S, Kallen K-J. The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma membrane. FEBS Lett. 2003;538:113–6.
    1. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M. et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer. 1994;57:318–23.
    1. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med. 1989;169:333–8.
    1. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N. et al. Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130. J Immunol. 2003;171:3202–9.
    1. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T. et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 1992;148:2175–80.
    1. Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Korschenhausen D, Greenberg BD. et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol. 1999;99:218–23.
    1. Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ. et al. The IL-6R alpha chain controls lung CD4+CD4+CD25+T regulatory cell development and function during allergic airway inflammation in vivo. J Clin Invest. 2005;115:313–25.
    1. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A. et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:281–90.
    1. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88.
    1. Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F. et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011;286:42959–70.
    1. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN. et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–13.
    1. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–24.
    1. Boekholdt SM, Stroes ES. The interleukin-6 pathway and atherosclerosis. Lancet. 2012;379:1176–8.
    1. Scheller J, Rose-John S. The interleukin 6 pathway and atherosclerosis. Lancet. 2012;380:338.
    1. Sodenkamp J, Waetzig GH, Scheller J, Seegert D, Grotzinger J, Rose-John S. et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology. 2012 in press.
    1. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S. et al. IL-6 and STAT3 signaling is required for survival of intestinal epithelial cells and colitis associated cancer. Cancer Cell. 2009;16:103–13.
    1. Dann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K, Choi LJ. et al. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol. 2008;180:6816–26.
    1. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501.
    1. Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M. et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011;39:1407–13.
    1. Chalaris A, Gewiese J, Paliga K, Fleig L, Schneede A, Krieger K. et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta. 2010;1803:234–45.
    1. Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman Kien AE. et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839–42.
    1. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi`s Sarcoma-associated Herpesvirus-encoded Cytokine Homolog (vIL-6) Activates Signaling through the Shared gp130 Receptor Subunit. J Biol Chem. 1997;272:19625–31.
    1. Müllberg J, Geib T, Jostock T, Hoischen SH, Vollmer P, Voltz N. et al. IL-6-Receptor Independent Stimulation of Human gp130 by Viral IL-6. J Immunol. 2000;164:4672–7.
    1. Hoischen SH, Vollmer P, Marz P, Ozbek S, Gotze KS, Peschel C. et al. Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem / FEBS J. 2000;267:3604–12.
    1. Chow D, He X, Snow AL, Rose-John S, Garcia KC. Structure of an extracellular gp130 cytokine receptor signaling complex. Science. 2001;291:2150–5.
    1. Adam N, Rabe B, Suthaus J, Grotzinger J, Rose-John S, Scheller J. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol. 2009;83:5117–26.
    1. Kovaleva M, Bussmeyer I, Rabe B, Grotzinger J, Sudarman E, Eichler J. et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol. 2006;80:8510–20.
    1. Meads MB, Medveczky PG. Kaposi's sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J Biol Chem. 2004;279:51793–803.
    1. Klouche M, Brockmeyer N, Knabbe C, Rose-John S. Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells. Aids. 2002;16:F9–18.
    1. Klouche M, Carruba G, Castagnetta L, Rose-John S. Virokines in the pathogenesis of cancer: focus on human herpesvirus 8. Ann N Y Acad Sci. 2004;1028:329–39.
    1. Suthaus J, Adam N, Grotzinger J, Scheller J, Rose-John S. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. Eur J Cell Biol. 2011;90:495–504.
    1. Fielding CA, McLoughlin RM, Colmont CS, Kovaleva M, Harris DA, Rose-John S. et al. Viral IL-6 blocks neutrophil infiltration during acute inflammation. J Immunol. 2005;175:4024–9.
    1. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G. et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood. 2012;119:5173–81.
    1. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals Hatem D, Babinet P. et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276–80.
    1. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–3.
    1. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15:91–102.
    1. Tanaka T, Narazaki M, Kishimoto T. Therapeutic Targeting of the Interleukin-6 Receptor. Annu Rev Pharmacol Toxicol. 2012;52:199–219.
    1. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S. et al. Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells. Nat Med. 2000;6:583–8.
    1. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N. et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut. 2006;55:1263–9.
    1. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS. et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111:1021–8.
    1. Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ. et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. Journal of immunology. 2011;186:1199–208.
    1. Finotto S, Eigenbrod T, Karwot R, Boross I, Doganci A, Ito H. et al. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol. 2007;19:685–93.
    1. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M. et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184:1543–51.
    1. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM. et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71:424–34.
    1. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19:456–69.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe